We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVRG.L Regulatory News (DVRG)

  • There is currently no data for DVRG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

U.S. launch of Skin Trust Club at Beauty Connect

11 Nov 2021 07:00

RNS Number : 0057S
Deepverge PLC
11 November 2021
 

11 November 2021

DeepVerge PLC

 

("DeepVerge" or "the Company")

 

U.S. launch of Skin Trust Club at Beauty Connect in Los Angeles

 

B2C and B2B offerings unveiled

 

 

 

DeepVerge (LSE:DVRG.L), announces that the Skin Trust Club is live in the U.S. following its launch to industry at Beauty Connect, Los Angeles on 4-5 November 2021. The U.S. launch is part of a five-event roadshow to industry that is unveiling what Skin Trust Club is all about and illustrating its power as a new game changing service in the skin health business.

 

At industry events in London (Pure Beauty) on 28 October 2021, Los Angeles (Beauty Connect) 4-5 November 2021, Boston (Microbiome Connect) 17-18 November 2021, Amsterdam (Microbiome Connect) 7-8 December 2021 and San Francisco (Personalised Beauty Summit) 30-31 March 2021, scientists from DeepVerge are briefing industry on the facets of the Skin Trust Club service:

 

· A science based personalised skincare service for consumers;

· A clinical trial for industry where microbiome samples are collected before, during and after trials to see granular effects;

· A personalised shopping experience where Skin Trust Club customers only see products relevant to their skin with science and AI based recommendations for skin health routines; and

· A databank of thousands of skin sample data with AI models constantly learning about different types of skin and the effects of lifestyle, medications, environment and skin products and ingredients on that skin.

 

With Skin Trust Club laboratories in York, UK, and Delaware, US, and a new laboratory in Cork, Ireland, coming online to serve the EU market, Skin Trust Club is available in two major markets - UK and US - and will also be available in selected EU countries by the end of this year.

 

Gerard Brandon, CEO of DeepVerge, commented:

"With the service now available across all platforms and an in-house back office system that has been tested at scale, we are now showing the power of the service as a B2C offering but also as a game changing B2B offering. The industry is realising that with Skin Trust Club, the Holy Grail of personalised beauty and skincare is here. Our partner programme is seeing leading brands sign up to sell the service as part of their product/service offerings, to use the service as part of their clinical trials and finally to see the impact the largest skin microbiome database in the world can have on moving skin science and their research forward.

 

"With Skin Trust Club, we've had moments where servers were overloaded with demand and where partners are imploring us to move into their core markets quicker than we initially planned. Thankfully by making the strategic decision to build everything in-house - sequencing, software, AI - thereby controlling the normalisation of the service, we have the flexibility to move fast to scale. With exciting events this year and a roadmap that includes replicating the service for scalp, hands, legs and feet, both industry and consumers know that the future of skincare is based on deep science.

 

"As a business, we are also seeing the full impact of the synergies within our business where our Labskin and Data/AI companies are working hand-in-hand to create a new service that the Board believes will have a profound effect on the skin health industry worldwide."

 

 

For further information please contact:

 

DeepVerge plc

Gerard Brandon, CEO

 

+44 (0) 7340 055 648

SPARK Advisory Partners Limited

(Nominated Adviser)

 

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker/James Pope

+44 (0) 20 3657 0050

 

About DeepVerge plc (www.deepverge.com)

DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins. Utilising artificial intelligent data analytics to scientifically prove the impact of skincare product claims on skin microbiome for most of the top 20 global cosmetic company clients and remotely detect and identify in real-time, dangerous pathogens in wastewater treatment plants, drinking water, rivers, lakes and reservoirs.

 

Labskin (Life Science Division)

Labskin have been pioneering the development of a laboratory grown human skin platform for more than 13 years and is the only commercially available lab-grown full thickness human skin model that naturally mimic the skin's microbiome. With top 20 global consumer health and skincare clients, thousands of industry tests, the good and bad bacteria that naturally exists on human skin is present on Labskin when testing skin care, cosmetics, health care, drug delivery or wound care products. The Labskin test platform and protocols help clients maintain an optimum real-world environment, when testing their new ingredients and existing skincare products, that shows the positive or negative impact on skin's natural microflora.

 

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRADKKBBOBDDKDD
Date   Source Headline
27th Dec 20237:00 amRNSCancellation - DEEPVERGE PLC
20th Dec 202312:30 pmRNSUpdate; exclusivity agreement with Microsaic
13th Dec 20234:38 pmRNSUpdate
14th Sep 20237:00 amRNSNew Website, Update
7th Aug 20232:30 pmRNSDisposal;Update; Related Party Trans'n-replacement
7th Aug 20237:00 amRNSDisposal; Update
2nd Aug 20239:35 amRNSBoard Change
1st Aug 20237:00 amRNSCompany Secretary Change
12th Jul 20237:00 amRNSUpdate
5th Jul 202311:26 amRNSUpdate
26th Jun 20237:30 amRNSSuspension - Deepverge PLC
26th Jun 20237:00 amRNSSale or closure of subsidiaries; share suspension
5th Jun 20237:00 amRNSCost reductions;delay to Ann. Report;New contract
19th Apr 20231:21 pmRNSMicrosaic Creditor; Update
17th Apr 20237:00 amRNS2022 revenue update - revision
24th Mar 202310:24 amRNSChange of Auditor
6th Mar 20234:35 pmRNSPrice Monitoring Extension
6th Mar 20232:05 pmRNSSecond Price Monitoring Extn
6th Mar 20232:00 pmRNSPrice Monitoring Extension
22nd Feb 20234:40 pmRNSSecond Price Monitoring Extn
22nd Feb 20234:35 pmRNSPrice Monitoring Extension
7th Feb 20237:00 amRNSBoard Appointment
6th Feb 20235:30 pmRNSSignificant contract win and Board change
2nd Feb 20234:40 pmRNSSecond Price Monitoring Extn
2nd Feb 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20237:00 amRNS2022 Revenue Update
23rd Nov 20224:10 pmRNSTR-1: Notification of major holdings
22nd Nov 20227:00 amRNSAccelerated Restructuring
16th Nov 20229:00 amRNSDirector/PDMR Shareholding
14th Nov 202212:16 pmRNSResult of Meeting
11th Nov 20224:37 pmRNSHolding(s) in Company
7th Nov 20227:00 amRNSDirectorate and Management Changes
3rd Nov 202212:32 pmRNSDirectorate Change
1st Nov 20223:56 pmRNSResult of Broker Offer; Total Voting Rights
31st Oct 20222:23 pmRNSBroker Offer to raise a max of £2.5m - replacement
31st Oct 20222:18 pmRNSExtension of Broker Offer to 430pm on 31 October
28th Oct 20221:06 pmRNSExtension of Broker Offer
27th Oct 20227:01 amRNSBroker Offer to raise a maximum of £2.5m
27th Oct 20227:00 amRNS£10m Placing, Broker Option, RPTs, Notice of GM
25th Oct 20222:05 pmRNSSecond Price Monitoring Extn
25th Oct 20222:00 pmRNSPrice Monitoring Extension
25th Oct 20227:01 amRNSUpdate - Proposed Financing,Proposed Board Changes
25th Oct 20227:00 amRNSHistorical Related Party Transactions
12th Oct 20224:41 pmRNSSecond Price Monitoring Extn
12th Oct 20224:35 pmRNSPrice Monitoring Extension
12th Oct 20227:04 amRNSResponse to Market Speculation
11th Oct 202211:05 amRNSSecond Price Monitoring Extn
11th Oct 202211:00 amRNSPrice Monitoring Extension
4th Oct 20227:00 amRNSLabskin contract
30th Sep 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.